RIP1 activation and pathogenesis of NASH

arigo is proud to announce that our RIP1 pSer166 antibody (ARG66476) was used for studying the pathogenesis of NASH and published in Cell Death Differ.

Non-alcoholic steatohepatitis (NASH), a type of fatty liver disease, is characterized by inflammation and concurrent fat accumulation in liver. NASH may lead to liver fibrosis, cirrhosis, and liver cancer. By using RIP1 activation marker RIP1 pSer166 antibody (ARG66476), Tao et al., demonstrated that kinase activity of RIP1 in macrophages contributes to the pathogenesis of NASH, through mediating pyroptosis, apoptosis, and necroptosis (PANoptosis). Their result indicates that macrophage RIP1 represents a potential therapeutic target for NASH.

arigo offers smart solutions including RIP1 activation marker and antibody duos/panels for PANoptosis to facilitate the research of NASH pathogenesis.

RIP1 pSer166 antibody [YJY-1-5] (ARG66476)

Rabbit mAb
Reactivity: Ms, Rat
Application: ICC/IF, IHC-Fr, IHC-P, IP, WB

Necrosome Antibody Panel (ARG30344)

● Includes key component RIP1, RIP3, and MLKL antibodies
● Works on human and mouse samples

 Necroptosis Marker Antibodies 

RIP3 pSer232 antibody (ARG41235)
Reactivity: Ms
Application: WB

MLKL pSer358 antibody (ARG40184)
Reactivity: Hu
Application: IHC-P, WB

 Pyroptosis & Inflammasome 

Pyroptosis Antibody Panel (ARG30330)

● Caspase-1 antibody
​● GSDMD antibody
● IL-1 beta antibody [SQab1748]
● beta-Tubulin antibody [BT7R]

NLRP3 Inflammasome Antibody Panel (ARG30331)

● NLRP3 antibody
​● ASC antibody
● Caspase-1 antibody
● GAPDH antibody [6C5]

M1/M2/TAM Marker Antibody Panel (ARG30333)

● Includes the antibody markers for M1, M2, and TAMs.
● Excellent for studying macrophage polarization.
● Outstanding performance in IHC staining.
● Good for double staining. 

You may be interested in…

arigo minifilm - Inflammasome & Pyroptosis

Total solution for HMGB1 research